Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination
X-Chem and AstraZeneca: Innovative technology partnership to identify lead molecules for drug discovery
An IMED Collaboration Update
Since 2012, we’ve been working with US-based X-Chem Inc. to improve the rate and quality of small molecule lead discovery and expand the realm of 'druggable' targets. X-Chem’s proprietary high-diversity library and ultra-efficient screening platform has been highly successful against historically challenging targets, including protein-protein interactions; epigenetic targets, the Ubiquitin family, antibacterial targets and G-protein coupled receptors. Our successful pilot programme focused on 20 targets. A year later, we expanded the collaboration to multiple therapy areas.Download collaboration update (PDF 1990kb)
All Directors are collectively responsible for the success of AstraZeneca. Discover general information, images and biographies of our Board of Directors.
AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.
Path to new medicines
The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.
Visit our dedicated neuroscience site for more information on our research and partnering in the area.
Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines